We use cookies to make it easier for you to use our website and give you a better experience. We aggregate the information we get through cookies from users like you, and analyze that data to better understand user behavior and help us improve the website. We do not give or sell the data you provide through cookies to any third party for any purpose (such as advertising or marketing). By using this website, you consent to Organogenesis using cookies for these purposes. You may change your settings anytime by clicking on the “Security” tab on your browser. Note that Organogenesis is located in the United States, and the U.S. has not yet been determined to have “adequate” data privacy safeguards by the EU; despite any inherent risks in the transfer of data from the EU, Organogenesis takes the security of your information seriously. To read our privacy policy, click here.

PuraPly® Antimicrobial (Advanced Wound Care)

PuraPly®

PuraPly® Antimicrobial (PuraPly® AM) Wound Matrix is an FDA 510(k)-cleared Class II medical device that is indicated for the management of a variety of acute and chronic wound types, including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, trauma wounds, draining wounds, and first- and second-degree burns.1

PuraPly Antimicrobial Wound Matrix (PuraPly AM) consists of a collagen sheet coated with 0.1% polyhexmethylenebiguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single pouches.1

PuraPly AM utilizes a purified native collagen matrix embedded with the antimicrobial polyhexamethylene biguanide, or PHMB, a broad spectrum antimicrobial. It is this combination of native collagen and PHMB that helps manage the reformation of biofilm while supporting healing across a wide variety of wound types, regardless of severity or duration.2,3,4

Launched in 2016, PuraPly AM is part of BBWM™, a proactive approach which aims to reduce and manage the reformation of biofilm with sharp debridement and the use of PuraPly AM.4

PuraPly AM has been named one of the “Top 10 Innovations in Podiatry” by Podiatry Today, a publication that covers the latest developments in podiatric medicine.

For more information on PuraPly AM please visit www.puraplyam.com.


  1. PuraPly antimicrobial [package insert]. Canton, MA: Organogenesis, Inc; 2015
  2. Hübner NO, Kramer A. Skin Pharmacol Physiol. 2010;23(suppl):17-27
  3. Negron L et al. Int Wound J. 2014;11:392-397.
  4. Wolcott RD et al. J Wound Care. 2010;19(8):320-328.